Short Interest in VolitionRX Limited (NYSEAMERICAN:VNRX) Grows By 65.3%

VolitionRX Limited (NYSEAMERICAN:VNRX) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 1,118,479 shares, a growth of 65.3% from the December 31st total of 676,713 shares. Currently, 1.0% of the company’s stock are short sold. Based on an average daily volume of 2,519,261 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily volume of 2,519,261 shares, the days-to-cover ratio is currently 0.4 days. Currently, 1.0% of the company’s stock are short sold.

VolitionRX Trading Up 13.5%

NYSEAMERICAN:VNRX opened at $0.29 on Monday. The stock has a market capitalization of $37.33 million, a PE ratio of -1.24 and a beta of 1.28. VolitionRX has a 1-year low of $0.22 and a 1-year high of $0.94. The firm has a fifty day simple moving average of $0.28 and a 200 day simple moving average of $0.47.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.